Insider Selling: Beta Bionics (NASDAQ:BBNX) Director Sells $21,090.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 1,406 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $15.00, for a total value of $21,090.00. Following the transaction, the director owned 25,994 shares in the company, valued at $389,910. This trade represents a 5.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, June 4th, Christy Jones sold 2,811 shares of Beta Bionics stock. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00.
• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total transaction of $19,880.10.

Beta Bionics Stock Up 5.7%

BBNX opened at $16.82 on Friday. The firm’s fifty day simple moving average is $12.13 and its two-hundred day simple moving average is $15.58. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The company has a market cap of $749.50 million, a price-to-earnings ratio of -11.14 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million during the quarter. On average, research analysts forecast that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on BBNX shares. Stifel Nicolaus reduced their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Truist Financial lowered their price target on Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Weiss Ratings lowered Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Finally, Leerink Partners reduced their price objective on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.

Hedge Funds Weigh In On Beta Bionics

Institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Beta Bionics during the 1st quarter valued at about $95,000. Goldman Sachs Group Inc. purchased a new position in Beta Bionics in the 1st quarter worth approximately $715,000. Woodline Partners LP acquired a new position in shares of Beta Bionics during the 1st quarter worth approximately $1,530,000. Strs Ohio acquired a new position in shares of Beta Bionics during the 1st quarter worth approximately $29,000. Finally, Rhumbline Advisers acquired a new position in shares of Beta Bionics during the 1st quarter worth approximately $158,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.